LegalApr 27, 2026, 08:38 AM
ERAS Faces Patent Infringement Claims from RevMed on ERAS-0015
AI Summary
Erasca, Inc. announced it received a letter from Revolution Medicines, Inc. alleging patent infringement and trade secret misappropriation related to Erasca's pan-RAS molecular glue ERAS-0015. RevMed demanded Erasca cease all activities related to ERAS-0015 in the U.S. and stop comparative statements. Erasca believes the allegations are without merit and plans to contest them vigorously. Additionally, Erasca will host a conference call today to discuss preliminary Phase 1 dose escalation data for ERAS-0015.
Key Highlights
- Revolution Medicines alleges ERAS-0015 infringes U.S. Patent No. 12,409,225.
- RevMed claims trade secret misappropriation related to ERAS-0015.
- RevMed demanded Erasca cease all ERAS-0015 activities in the U.S.
- RevMed demanded Erasca stop comparative statements of ERAS-0015 and RMC-6236.
- Erasca believes allegations are without merit and will contest them vigorously.
- Erasca will host a conference call today to discuss preliminary Phase 1 data for ERAS-0015.